Fig. 7
From: SAMD13 serves as a useful prognostic biomarker for hepatocellular carcinoma
SAMD13 is upregulated in chemotherapeutic drug-resistant HCC. A Expression of SAMD13 in cisplatin- or doxorubicin-resistant (GSE54175), sorafenib-resistant (GSE121153), doxorubicin-resistant (GSE125180), and JNJ-28841072-resistant cells (GSE93595) was shown by analyzing the GEO database. B SAMD13 levels was determined in HCC patients responding or non-responding to sorafenib treatment or not.–, parent cells; Cis, in vitro Cisplatin-resistant subclones; Dox, in vitro Doxorubicin-resistant subclones; Sor, in vitro Sorafenib-resistant subclones; F6, in vivo drug-tolerant subclones (6 months); F12, in vivo drug-tolerant subclones (12 months). C Heat-map plot of Spearman’s correlation between SAMD13 and ICB related genes from TCGA–LIHC data set